MA38961A1 - Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose - Google Patents

Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose

Info

Publication number
MA38961A1
MA38961A1 MA38961A MA38961A MA38961A1 MA 38961 A1 MA38961 A1 MA 38961A1 MA 38961 A MA38961 A MA 38961A MA 38961 A MA38961 A MA 38961A MA 38961 A1 MA38961 A1 MA 38961A1
Authority
MA
Morocco
Prior art keywords
cancer
autoimmune
tyrosine kinase
inflammatory diseases
mastocytosis
Prior art date
Application number
MA38961A
Other languages
English (en)
Inventor
Wei Chen
David Loury
Longcheng Wang
Zhaozhong Jia
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MA38961A1 publication Critical patent/MA38961A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés qui forment des liaisons covalentes avec la tyrosine kinase de bruton (btk). L'invention concerne également des inhibiteurs irréversibles de btk. De plus, des inhibiteurs réversibles de btk sont également décrits. L'invention concerne également des compositions pharmaceutiques qui comprennent les composés. L'invention concerne de plus des procédés d'utilisation des inhibiteurs de btk, seuls ou en combinaison avec d'autres agents thérapeutiques, pour le traitement de maladies ou d'états auto-immuns, de maladies ou d'états hétéro-immuns, du cancer, comprenant un lymphome, et de maladies ou d'états inflammatoires.
MA38961A 2013-09-30 2014-09-29 Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose MA38961A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361884888P 2013-09-30 2013-09-30
PCT/US2014/058132 WO2015048689A1 (fr) 2013-09-30 2014-09-29 Inhibiteurs de la tyrosine kinase de bruton

Publications (1)

Publication Number Publication Date
MA38961A1 true MA38961A1 (fr) 2018-05-31

Family

ID=52740746

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38961A MA38961A1 (fr) 2013-09-30 2014-09-29 Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose

Country Status (20)

Country Link
US (2) US9624224B2 (fr)
EP (1) EP3052486A1 (fr)
JP (1) JP2016531941A (fr)
KR (1) KR20160062103A (fr)
CN (1) CN105764896A (fr)
AR (1) AR097862A1 (fr)
AU (1) AU2014324532A1 (fr)
BR (1) BR112016006978A2 (fr)
CA (1) CA2925124A1 (fr)
CR (1) CR20160203A (fr)
DO (1) DOP2016000071A (fr)
EA (1) EA201690618A1 (fr)
IL (1) IL244492A0 (fr)
MA (1) MA38961A1 (fr)
PE (1) PE20160560A1 (fr)
PH (1) PH12016500575A1 (fr)
SG (1) SG11201602421VA (fr)
TN (1) TN2016000094A1 (fr)
TW (1) TW201546061A (fr)
WO (1) WO2015048689A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ736048A (en) 2010-06-03 2019-09-27 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
EP3812387A1 (fr) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de protéine kinase hétérocycliques
EP2877598A1 (fr) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associées à la résistance à des inhibiteurs de la tyrosine kinase de bruton (btk)
CN108997225A (zh) 2013-03-14 2018-12-14 特雷罗药物股份有限公司 Jak2和alk2抑制剂及其使用方法
US9637487B2 (en) 2013-07-02 2017-05-02 Pharmacyclics Llc Purinone compounds as kinase inhibitors
EP3119910A4 (fr) 2014-03-20 2018-02-21 Pharmacyclics LLC Mutations de phospholipase c gamma 2 et associées aux résistances
CN107021963A (zh) * 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
CN108602834B (zh) * 2016-02-05 2021-01-08 北京盛诺基医药科技股份有限公司 一种布鲁顿酪氨酸激酶抑制剂
JP2020511462A (ja) 2016-12-03 2020-04-16 ジュノー セラピューティクス インコーポレイテッド キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物
KR101956815B1 (ko) 2017-02-14 2019-03-12 한국화학연구원 트리아졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
AU2018224136B2 (en) 2017-02-24 2021-10-21 Gilead Sciences, Inc. Inhibitors of Bruton's Tyrosine Kinase
US10314844B2 (en) 2017-02-24 2019-06-11 Gilead Sciences, Inc. Inhibitors of Bruton's tyrosine kinase
CN108570036A (zh) * 2017-03-09 2018-09-25 北京赛林泰医药技术有限公司 一种btk抑制剂的多晶型物及其制备方法
WO2018208132A1 (fr) * 2017-05-12 2018-11-15 Korea Research Institute Of Chemical Technology Dérivés de pyrazolopyrimidine, leur procédé de préparation et composition pharmaceutique pour utilisation dans la prévention ou le traitement du cancer, d'une maladie auto-immune et d'une maladie du cerveau contenant ceux-ci en tant que principe actif
KR102128018B1 (ko) 2017-05-12 2020-06-30 한국화학연구원 피라졸로 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암, 자가면역질환 및 뇌질환의 예방 또는 치료용 약학적 조성물
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
WO2019090269A1 (fr) 2017-11-06 2019-05-09 Peng Wang Processus de production de l'acalabrutinib
CN109748929A (zh) * 2017-11-06 2019-05-14 苏州鹏旭医药科技有限公司 一种化合物的制备方法
WO2019195753A1 (fr) 2018-04-05 2019-10-10 Tolero Pharmaceuticals, Inc. Inhibiteurs de kinases axl et leur utilisation
MX2020010556A (es) 2018-04-13 2021-03-02 Sumitomo Pharma Oncology Inc Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
EP3826684A4 (fr) 2018-07-26 2022-04-06 Sumitomo Dainippon Pharma Oncology, Inc. Procédés de traitement de maladies associées à l'expression anormale d'acvr1 et inhibiteurs d'acvr1 destinés à être utilisés dans ceux-ci
CN110964016B (zh) * 2018-09-29 2021-05-28 南京药捷安康生物科技有限公司 氨基降茨烷衍生物及其制备方法与应用
CN113412262A (zh) 2019-02-12 2021-09-17 大日本住友制药肿瘤公司 包含杂环蛋白激酶抑制剂的制剂
EP3942045A1 (fr) 2019-03-21 2022-01-26 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
WO2020252397A1 (fr) * 2019-06-12 2020-12-17 Baylor College Of Medicine Chimères ciblant la protéolyse à petites molécules et leurs méthodes d'utilisation
CN111018865B (zh) * 2019-10-17 2021-01-15 山东大学 1-取代苄基吡唑并嘧啶衍生物及其制备方法与应用
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN112961159B (zh) * 2020-03-05 2022-07-01 四川大学华西医院 氨基嘧啶并吡唑/吡咯类衍生物及其制备方法和用途
WO2022140246A1 (fr) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Procédés et composés destinés à l'autophagie ciblée
KR102637915B1 (ko) 2021-06-25 2024-02-19 한국화학연구원 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도
BR112023025403A2 (pt) 2021-06-25 2024-02-20 Korea Res Inst Chemical Tech Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo
CA3233636A1 (fr) * 2021-09-29 2023-04-06 Repare Therapeutics Inc. Composes n-([(l,3,4-thiadiazolyle) ou (thiazolyle)]-5-substitues)carboxamide (substitue) et leur utilisation pour inhiber la polymerase theta humaine
AU2022380336A1 (en) 2021-11-05 2024-05-30 Ubix Therapeutics, Inc. Compound having btk protein degradation activity, and medical uses thereof
CN113968860B (zh) * 2021-11-05 2023-06-06 杭州医学院 一种可逆btk抑制剂及其合成方法和应用
CN114213416B (zh) * 2021-11-05 2023-06-06 杭州医学院 一种恶唑并[4,5-b]吡啶结构的不可逆BTK抑制剂及其应用
WO2024069592A1 (fr) * 2022-09-29 2024-04-04 Repare Therapeutics Inc. Composés de n-([(l, 3,4-thiadiazolyle) substitué en position 5 ou (l,3-thiazolyl)](substitué)carboxamide, compositions pharmaceutiques et procédés de préparation de composés amides et leur utilisation
WO2024097653A1 (fr) 2022-10-31 2024-05-10 Sumitomo Pharma America, Inc. Inhibiteur de pim-1 pour le traitement de néoplasmes myéloprolifératifs

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01167840A (ja) 1987-12-24 1989-07-03 Konica Corp 新規な写真用シアンカプラー
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
NZ337529A (en) 1997-03-19 2000-10-27 Basf Ag Pyrrolo[2,3-d]pyrimidine derivatives useful as tyrosine kinase inhibitors
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
WO1999054286A2 (fr) 1998-04-17 1999-10-28 Parker Hughes Institute Inhibiteurs btk et leurs procedes d'identification et d'utilisation
US20050287596A9 (en) 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
ID29028A (id) 1998-09-18 2001-07-26 Basf Ag Pirolopirimidina sebagai penghambat protein kinase
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
CZ2002936A3 (cs) 1999-09-17 2002-10-16 Abbott Gmbh & Co. Kg Pyrazolopyrimidiny jako terapeutické prostředky
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
DE60014130T2 (de) 1999-10-06 2006-03-09 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
EP1235567A2 (fr) 1999-11-30 2002-09-04 Parker Hughes Institute Inhibiteurs d'agregation plaquettaire induite par le collagene
CA2394650A1 (fr) 1999-12-17 2001-06-21 Chi B. Vu Nouveaux heterocycles
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
AU2000240570A1 (en) 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
WO2002038797A2 (fr) 2000-10-23 2002-05-16 Bristol-Myers Squibb Company Modulateurs de tyrosine kinase de bruton et intermediaires de tyrosine kinase de bruton et leurs procedes d'identification et d'utilisation dans le traitement et la prevention de l'osteoporose et d'etats pathologiques connexes
EP1345592A2 (fr) 2000-12-06 2003-09-24 Pharmacia Corporation Composition pharmaceutique a dispersion rapide
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US8306897B2 (en) 2001-05-04 2012-11-06 Stockshield, Inc. Method and system for insuring against investment loss
AU2002315389A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
JP2005502643A (ja) 2001-08-10 2005-01-27 ノバルティス　アクチエンゲゼルシャフト 白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用
WO2003016338A1 (fr) 2001-08-15 2003-02-27 Parker Hughes Institute Structure cristalline du domaine kinase de btk
EP1446496A4 (fr) 2001-11-21 2005-03-30 Sunesis Pharmaceuticals Inc Procedes de decouverte de ligands
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
US7138420B2 (en) 2002-08-08 2006-11-21 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzimidazole compounds
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7687506B2 (en) 2003-04-11 2010-03-30 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
WO2004100868A2 (fr) 2003-04-23 2004-11-25 Abbott Laboratories Procede servant a traiter le rejet d'un transplant
EP1473039A1 (fr) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Utilisation d'inhibiteurs et d'oligonucleotitides antisense de BTK pour le traitement de la mastocytose proliferative
WO2005014599A1 (fr) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines et methodes d'inhibition de la tyrosine kinase de bruton par de tels composes
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
RU2405784C2 (ru) 2003-10-15 2010-12-10 Оси Фармасьютикалз, Инк. Имидазопиразины в качестве ингибиторов тирозинкиназ
WO2005060956A1 (fr) 2003-12-12 2005-07-07 University Of Maryland, Baltimore Composes immunomodulateurs de ciblage et d'inhibition du site de liaison py+3 du domaine sh2 de la proteine p56 tyrosine kinase
BRPI0418031A (pt) 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
CA2554551A1 (fr) 2004-01-26 2005-10-13 Vertex Pharmaceuticals Incorporated Compositions utilisees en tant qu'inhibiteurs des proteines kinases
EP1730148A4 (fr) 2004-02-03 2009-08-19 Abbott Lab Utilisation d'aminobenzoxazoles comme agents therapeutiques
ITMI20041314A1 (it) 2004-06-30 2004-09-30 Nuvera Fuel Cells Europ Srl Dispositivo di raffreddamento per celle a combustibili a membrana
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
WO2006036941A2 (fr) 2004-09-27 2006-04-06 Kosan Biosciences Incorporated Inhibiteurs de kinases specifiques
KR20070063562A (ko) 2004-09-28 2007-06-19 얀센 파마슈티카 엔.브이. 치환 디피페리딘 ｃｃｒ２ 길항제
SG159549A1 (en) 2004-11-10 2010-03-30 Cgi Pharmaceuticals Inc Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
ES2543607T3 (es) 2005-03-10 2015-08-20 Gilead Connecticut, Inc. Ciertas amidas sustituidas, método de obtención, y método de su uso
AU2006247757B2 (en) 2005-05-13 2009-08-27 Irm, Llc Compounds and compositions as protein kinase inhibitors
EP1893612B1 (fr) 2005-06-22 2011-08-03 Plexxikon, Inc. Derives de pyrrolo [2, 3-b]pyridine utilises comme inhibiteurs de proteines kinases
WO2007058832A2 (fr) 2005-11-12 2007-05-24 Boehringer Ingelheim International Gmbh INHIBITEURS DES KINASES Tec
CA2636696A1 (fr) 2006-01-13 2007-08-02 Pharmacyclics, Inc. Inhibiteurs de tyrosine kinase et leurs utilisations
CA2858520A1 (fr) 2006-05-18 2007-11-29 Pharmacyclics Inc. Inhibiteurs de kinases intracellulaires
ES2537399T3 (es) 2006-09-22 2015-06-08 Pharmacyclics, Inc. Inhibidores de tirosina cinasa de Bruton
WO2008054827A2 (fr) 2006-11-03 2008-05-08 Pharmacyclics, Inc. Sonde d'activité de la tyrosine kinase de bruton et son procédé d'utilisation
NL2000640C2 (nl) 2007-03-05 2008-09-08 Stichting Wetsus Ct Of Excelle Werkwijze en systeem voor het zuiveren van een vloeistof.
BRPI0810086B1 (pt) 2007-03-28 2021-11-09 Pharmacyclics Llc Composto inibidor de tirosina quinase de bruton, uso do referido composto e composição farmacêutica
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US20150152115A1 (en) 2007-12-27 2015-06-04 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP3311818A3 (fr) 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibiteurs de tyrosine-kinase de bruton pour le traitement de tumeurs solides
WO2010028236A1 (fr) 2008-09-05 2010-03-11 Avila Therapeutics, Inc. Algorithme pour concevoir des inhibiteurs irréversibles
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
DK2473049T3 (en) * 2009-09-04 2019-04-01 Biogen Ma Inc INHIBITORS OF BRUTON'S TYROSINKINASE
JP2013504325A (ja) 2009-09-09 2013-02-07 アビラ セラピューティクス， インコーポレイテッド Ｐｉ３キナーゼインヒビターおよびその使用
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
RS55184B1 (sr) 2010-05-31 2017-01-31 Ono Pharmaceutical Co Derivat purinona kao inhibitor btk kinaze
NZ736048A (en) 2010-06-03 2019-09-27 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
SI2975042T1 (sl) 2010-06-23 2019-02-28 Hanmi Science Co., Ltd. Novi fuzirani derivati pirimidina za inhibicijo aktivnosti tirozin kinaze
MX355728B (es) 2011-05-17 2018-04-27 Univ California Inhibidores de cinasas.
EA025496B1 (ru) 2011-05-17 2016-12-30 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
WO2012158795A1 (fr) * 2011-05-17 2012-11-22 Principia Biopharma Inc. Dérivés de pyrazolopyrimidine utilisés comme inhibiteurs de tyrosine kinase
WO2013003629A2 (fr) 2011-06-28 2013-01-03 Pharmacyclics, Inc. Procédés et compositions visant à inhiber la résorption osseuse
JP2014520863A (ja) * 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
EP2548877A1 (fr) 2011-07-19 2013-01-23 MSD Oss B.V. Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
KR20190040370A (ko) 2012-06-04 2019-04-17 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
MX368112B (es) 2012-06-18 2019-09-18 Principia Biopharma Inc Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias.
EP2878601B1 (fr) 2012-07-27 2018-03-28 Riken Agent destiné à traiter ou à supprimer une récidive de leucémie myélogène aiguë
WO2014022569A1 (fr) 2012-08-03 2014-02-06 Principia Biopharma Inc. Traitement de la sécheresse oculaire
AU2013344656A1 (en) 2012-11-15 2015-06-04 Pharmacyclics Llc Pyrrolopyrimidine compounds as kinase inhibitors
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2015017812A1 (fr) 2013-08-02 2015-02-05 Pharmacyclics, Inc. Méthodes permettant de traiter des tumeurs solides
AU2014339816B2 (en) 2013-10-25 2020-05-28 Pharmacyclics Llc Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
CN103923084B (zh) 2014-01-29 2016-08-17 苏州晶云药物科技有限公司 几种晶型及其制备方法
WO2015127261A1 (fr) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarqueurs permettant de prédire la réponse du ldgcb à un traitement sous ibrutinib
EP3119910A4 (fr) 2014-03-20 2018-02-21 Pharmacyclics LLC Mutations de phospholipase c gamma 2 et associées aux résistances

Also Published As

Publication number Publication date
IL244492A0 (en) 2016-04-21
AR097862A1 (es) 2016-04-20
KR20160062103A (ko) 2016-06-01
CA2925124A1 (fr) 2015-04-02
PE20160560A1 (es) 2016-06-09
CR20160203A (es) 2016-08-31
CN105764896A (zh) 2016-07-13
US20150094319A1 (en) 2015-04-02
JP2016531941A (ja) 2016-10-13
WO2015048689A8 (fr) 2015-05-07
US9624224B2 (en) 2017-04-18
TN2016000094A1 (en) 2017-07-05
AU2014324532A1 (en) 2016-04-21
EP3052486A1 (fr) 2016-08-10
EA201690618A1 (ru) 2016-09-30
SG11201602421VA (en) 2016-04-28
US20170050970A1 (en) 2017-02-23
DOP2016000071A (es) 2016-09-15
TW201546061A (zh) 2015-12-16
WO2015048689A1 (fr) 2015-04-02
BR112016006978A2 (pt) 2017-08-01
PH12016500575A1 (en) 2016-07-25

Similar Documents

Publication Publication Date Title
MA38961A1 (fr) Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
TN2015000168A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
MX2021015368A (es) Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX2017001671A (es) Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
EA202091709A1 (ru) Ингибиторы днк-пк
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
EA202091708A1 (ru) Ингибиторы днк-пк
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
MA38056A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
MA51297B1 (fr) Quinazolinones en tant qu'inhibiteurs de parp14
MA45367B1 (fr) Inhibiteurs de la tyrosine kinase
MA41643B1 (fr) Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton